These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8159701)

  • 1. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition.
    Myatt EA; Westholm FA; Weiss DT; Solomon A; Schiffer M; Stevens FJ
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3034-8. PubMed ID: 8159701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxic potential of Bence Jones proteins.
    Solomon A; Weiss DT; Kattine AA
    N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma.
    Iványi B
    Arch Pathol Lab Med; 1990 Sep; 114(9):986-7. PubMed ID: 2117910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
    Harris DL; King E; Ramsland PA; Edmundson AB
    J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases.
    Sikkink LA; Ramirez-Alvarado M
    Amyloid; 2008 Mar; 15(1):29-39. PubMed ID: 18266119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.
    Buxbaum J; Gallo G
    Hematol Oncol Clin North Am; 1999 Dec; 13(6):1235-48. PubMed ID: 10626147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR).
    Odani S; Komori Y; Gejyo F
    Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains.
    Davern S; Murphy CL; O'Neill H; Wall JS; Weiss DT; Solomon A
    Biochim Biophys Acta; 2011 Jan; 1812(1):32-40. PubMed ID: 20692337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues.
    Foss GS; Nilsen R; Cornwell GC; Husby G; Sletten K
    Scand J Immunol; 1998 Apr; 47(4):348-54. PubMed ID: 9600316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits.
    Gallo G; Goñi F; Boctor F; Vidal R; Kumar A; Stevens FJ; Frangione B; Ghiso J
    Am J Pathol; 1996 May; 148(5):1397-406. PubMed ID: 8623912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients.
    Blancas-Mejía LM; Martin EB; Williams A; Wall JS; Ramirez-Alvarado M
    Biophys Chem; 2017 Nov; 230():89-98. PubMed ID: 28916410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction in mice of human light-chain-associated amyloidosis.
    Solomon A; Weiss DT; Pepys MB
    Am J Pathol; 1992 Mar; 140(3):629-37. PubMed ID: 1546744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bence Jones proteins and light chains of immunoglobulins. XIII. Effect of elastase-like and chymotrypsin-like neutral proteases derived from human granulocytes on Bence Jones proteins.
    Solomon A; Schmidt W; Havemann K
    J Immunol; 1976 Sep; 117(3):1010-4. PubMed ID: 60445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of single point mutations in a form of systemic amyloidosis.
    Bhavaraju M; Hansmann UH
    Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins.
    Stevens PW; Raffen R; Hanson DK; Deng YL; Berrios-Hammond M; Westholm FA; Murphy C; Eulitz M; Wetzel R; Solomon A
    Protein Sci; 1995 Mar; 4(3):421-32. PubMed ID: 7795526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and treatment of myeloma kidney.
    Sanders PW
    J Lab Clin Med; 1994 Oct; 124(4):484-8. PubMed ID: 7930873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of a Single Point Mutation in the Constant Domain of the Bence-Jones Protein bif on Its Aggregation Properties.
    Timchenko MA; Timchenko AA
    Biochemistry (Mosc); 2018 Feb; 83(2):107-118. PubMed ID: 29618297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.
    Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M
    PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal lesions in plasma cell dyscrasias: ultrastructural observations.
    Pirani CL; Silva F; D'Agati V; Chander P; Striker LM
    Am J Kidney Dis; 1987 Sep; 10(3):208-21. PubMed ID: 3115092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.